ACC 2014:CRT-D可降充血性心衰事件发生率及死亡率

2014-04-10 高晓方 译 医学论坛网

2014年美国心脏病学会年会(ACC 2014)MADIT-CRT研究表明,在QRS波增宽且无症状或有轻微症状(NYHA 分级 I/II)的收缩期充血性心力衰竭(CHF)患者中,心脏再同步治疗除颤器(CRT-D)置入与CHF事件发生率及死亡率显著降低具有相关性。 此项研究共纳入1820例CHF高危患者,并以3:2的比率随机分入CRT-D组或ICD组。利用最新优化技术对CRT房室延搁实施最佳化,以

2014年美国心脏病学会年会(ACC 2014)MADIT-CRT研究表明,在QRS波增宽且无症状或有轻微症状(NYHA 分级 I/II)的收缩期充血性心力衰竭(CHF)患者中,心脏再同步治疗除颤器(CRT-D)置入与CHF事件发生率及死亡率显著降低具有相关性。

此项研究共纳入1820例CHF高危患者,并以3:2的比率随机分入CRT-D组或ICD组。利用最新优化技术对CRT房室延搁实施最佳化,以右心室起搏最小化为目标置入单腔或双腔ICD装置。主要终点为死亡或非致命性CHF事件。评估CRT-D能否降低全因死亡率和CHF事件发生率。

结果显示,两组患者的基线特征均相似。CRT-D组患者的主要终点发生率低于ICD组(17.2%对25.3%,HR 0.66),并且主要由CHF事件减少所引起。两组患者在全因死亡率方面无显著差异。在女性、QRS持续时间≥150毫秒以及伴LBBB患者获益更为显著。CRT-D组患者的30天不良事件发生率稍高于ICD组。随访7年时,CRT-D组伴LBBB患者的全因死亡、非致命性心衰和CHF/死亡均显著减少。


相关阅读:



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826251, encodeId=ab5b1826251a2, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Nov 27 04:45:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046321, encodeId=01af204632125, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Sep 21 03:45:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324918, encodeId=da2213249183e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341456, encodeId=02411341456ed, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517125, encodeId=a64c151e1259a, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826251, encodeId=ab5b1826251a2, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Nov 27 04:45:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046321, encodeId=01af204632125, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Sep 21 03:45:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324918, encodeId=da2213249183e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341456, encodeId=02411341456ed, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517125, encodeId=a64c151e1259a, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826251, encodeId=ab5b1826251a2, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Nov 27 04:45:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046321, encodeId=01af204632125, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Sep 21 03:45:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324918, encodeId=da2213249183e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341456, encodeId=02411341456ed, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517125, encodeId=a64c151e1259a, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826251, encodeId=ab5b1826251a2, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Nov 27 04:45:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046321, encodeId=01af204632125, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Sep 21 03:45:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324918, encodeId=da2213249183e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341456, encodeId=02411341456ed, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517125, encodeId=a64c151e1259a, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1826251, encodeId=ab5b1826251a2, content=<a href='/topic/show?id=e5283e89970' target=_blank style='color:#2F92EE;'>#发生率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37899, encryptionId=e5283e89970, topicName=发生率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Thu Nov 27 04:45:00 CST 2014, time=2014-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046321, encodeId=01af204632125, content=<a href='/topic/show?id=f02a285e0e1' target=_blank style='color:#2F92EE;'>#充血性心衰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28570, encryptionId=f02a285e0e1, topicName=充血性心衰)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Sep 21 03:45:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324918, encodeId=da2213249183e, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1341456, encodeId=02411341456ed, content=<a href='/topic/show?id=4310528ea7' target=_blank style='color:#2F92EE;'>#CRT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5287, encryptionId=4310528ea7, topicName=CRT)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517125, encodeId=a64c151e1259a, content=<a href='/topic/show?id=b06f528889' target=_blank style='color:#2F92EE;'>#CRT-D#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5288, encryptionId=b06f528889, topicName=CRT-D)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cf0c11038551, createdName=minhuang75_72521587, createdTime=Sat Apr 12 01:45:00 CST 2014, time=2014-04-12, status=1, ipAttribution=)]

相关资讯

Circulation Ep:心衰患者CRT-D植入后的LVEF与室性心律失常ICD治疗的关系

CRT(cardiac resynchronization therapy)可减轻心衰患者的心衰症状并减少住院次数,改善心衰患者预后。它可以提高一部分患者的左室射血分数(LVEF),在一个小规模的亚组研究中,尽管约25-30%的患者临床改善不明显,但CRT确实可使患者的心室功能接近正常,这部分患者称为超级反应患者(super-responders),其定义为CRT植入后LVEF>=45%。有

Heart:CRT-D未产生额外生存获益

英国一项研究表明,长期随访时心脏再同步治疗除颤器(CRT-D)未能产生额外生存获益。论文于4月1日在线发表于《心脏》(Heart)。 此项研究共纳入500例置入心脏再同步治疗装置的患者,其中置入仅起搏装置(CRT-P)和CRT-D的患者分别为354和146例。随访时间至少为2年,平均随访29个月。主要终点为全因死亡率。 结果显示,共记录116例(23.2%)死亡,CRT-P和CRT-D组分别为